Abstract
The American Association of Oral and Maxillofacial Surgeons (AAOMS) reported in 2004 a new pathology that causes osteonecrosis in the Maxillomandibular complex. The condition was named Bisphosphonate-related osteonecrosis of the jaw (BRONJ), and later renamed by medication related to jaw osteonecrosis due to the appearance of severe alveolar bone loss in the Maxillomandibular complex resulting from the use of different drugs other than Bisphosphonates. Odontology, especially oral surgery, a field concerned with newbiotechnologies, has been introducing innovations in tissue engineering. Oro-maxillofacial reconstruction is of great interest to current oral and maxillofacial surgeons, as part of the search for strategies in bioengineering and biomaterials, a major promoter of bio-dental research in our times. In order to verify the scientific evidences to analyse the effectiveness of leukocyte and platelet rich fibrin (L-PRF) on bone neoformation inMaxillomandibular complex’s surgical procedures, a search for qualified articles was conducted in the Medline (PubMed), Embase and Cochrane Central Register of Controlled Trials databases. The works analysed were published from 2013 to 2018. This review concludes that the use of platelet rich fibrin (L-PRF) is significant in the complete healing of the lesion in short postoperative periods and in the resolution of the treatments, reducing the need for postoperative re-interventions, resulting in lower morbidity for the patients
Highlights
Bisphosphonates are synthetic pharmacological substances that have high affinity for hydroxyapatite, analogous to pyrophosphates – a substance present in the bone matrix naturally – which act as anti-remodelling agents, used for treatments of metabolic bone diseases such as cancerous complications of bone metastases and in the prevention of osteoporosis[1,2]
A digital search was performed for relevant work in the Cochrane-Library (Cochrane), MEDLINE/Pub Med, Scopus and Embase databases, with no date or language limitation, articles dating from the year 2013 to September of 2018, related to the key words: “leukocyte and platelet-rich fibrin, L-PRF, platelet-rich fibrin, bisphosphonate-associated osteonecrosis of the jaw, bisphosphonate-associated osteonecrosis, bisphosphonate related osteonecrosis of the jaw”
The studies had to report the results of surgical procedures performed in patients with Medication-related osteonecrosis of the jaw (MRONJ) therapies, to whom L-PRF was the complementary therapy chosen for adjuvant use
Summary
Bisphosphonates are synthetic pharmacological substances that have high affinity for hydroxyapatite, analogous to pyrophosphates – a substance present in the bone matrix naturally – which act as anti-remodelling agents, used for treatments of metabolic bone diseases such as cancerous complications of bone metastases and in the prevention of osteoporosis[1,2] They are medicament widely prescribed and widely used for the treatment of osteoporosis and other chronical bone deceases; these synthetic agents have great affinity for calcium, acting on osteoclasts and osteoblasts, decreasing bone remodelling and inhibiting mediators of inflammation, decreasing bone turnover, altering the mechanism of bone tissue[3,4]. In 2006, several studies on BRONJ were reported[9,10,11]; since several professionals identified and demonstrated how to manage the illness, based on their empirical experience and opinions[12,13,14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
